Get the Stockscreener App
1.12
3.45%
-0.04
After Hours:
1.08
-0.04
-3.57%
Immuron Limited Adr stock is traded at $1.12, with a volume of 23,553.
It is down -3.45% in the last 24 hours and up +11.44% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
See More
Previous Close:
$1.16
Open:
$1.15
24h Volume:
23,553
Relative Volume:
0.13
Market Cap:
$9.15M
Revenue:
$4.83M
Net Income/Loss:
$-2.99M
P/E Ratio:
-2.3314
EPS:
-0.4804
Net Cash Flow:
$-2.83M
1W Performance:
-5.88%
1M Performance:
+11.44%
6M Performance:
+16.41%
1Y Performance:
-37.08%
1-Day Range:
$1.0501
$1.17
1-Week Range:
$1.05
$1.29
52-Week Range:
$0.6765
$2.39
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
1.12 | 9.47M | 4.83M | -2.99M | -2.83M | -0.4804 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuron Limited Adr Stock (IMRN) Latest News
Which stocks have an unusual volume on Thursday? - ChartMill
Immuron (NASDAQ: IMRN) responds to ASX query on share price - Stock Titan
Wondering what's happening in today's after-hours session? - ChartMill
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3 - Stock Titan
Number of shareholders of Immuron Limited Sponsored ADR – LSX:A2DTD8 - TradingView
Immuron (NASDAQ: IMRN) details TD portfolio growth and partnering push - Stock Titan
Immuron (IMRN) chairman discloses 1.67M share options - Stock Titan
Immuron (NASDAQ: IMRN) CEO schedules Emerging Growth Conference presentation - Stock Titan
IMRN - Finviz
Unusual VolumeStock ScreenerNews - Finviz
IMRN Stock Price, Quote & Chart | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron Double Digit 3Q Sales Growth - Sahm
Top 10 at 11: Wall Street hits all-time highs but ASX opens lower as banks retreat - MSN
Immuron (NASDAQ: IMRN) lifts Travelan sales with strong Canada Q3 surge - Stock Titan
Immuron (NASDAQ: IMRN) offers cost-free sale facility for small shareholdings - Stock Titan
Operating cash flow per share of Immuron Limited Sponsored ADR – GETTEX:ANWA - TradingView
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Democrat and Chronicle
IMRN Earnings History & Surprises | EPS & Revenue Results | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Sahm
Immuron (NASDAQ: IMRN) boosts cash, pursues partners for IMM-124E and IMM-529 - Stock Titan
Immuron Reports HY26 Results and Strategic Reset - GlobeNewswire Inc.
Immuron Reports HY26 Results and Strategic Reset - ChartMill
Immuron (NASDAQ: IMRN) gains A$1.12M non-dilutive R&D refund - Stock Titan
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - progress-index.com
Immuron Reports Continued Sales Growth - Finviz
Does Immuron Limited (Common Stock) (ANWA) stock trade below intrinsic valueJuly 2025 Spike Watch & Smart Investment Allocation Insights - DonanımHaber
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - The Globe and Mail
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com Australia
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com India
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
ANWA Forecast — Price Target — Prediction for 2026 - TradingView — Track All Markets
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - FinancialContent
Wondering what's happening in today's pre-market session? - ChartMill
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
Immuron IMM-529 IND approved by FDA - FinancialContent
Insights: Immuron Ltd (ASX:IMC) - smallcaps.com.au
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Submits IMM-529 IND to FDA - GlobeNewswire
Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales - Finviz
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):